Research uncovers how to target ‘sleeping’ breast cancer cells and pr
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.
Spring appeal 2024 hard to treat cancers
This preliminary retrospective study assessed patients with highly advanced hepatocellular carcinoma, exploring the efficacy and safety of concurrent atezo
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2…
Tumor-associated macrophages (TAMs) are well known to fuel tumor evolution. Blériot et al. advocate for integrating the time dimension when conceptualizing macrophage diversity in pre-malignancy and cancer…
Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL.…
Here, we summarize a post hoc analysis of the IDHENTIFY trial investigating the molecular characteristics and prognostic impact of co-occurring mutations in patients with R/R…
Priyanka Mehta, MBBS, MD, FRCP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, briefly discusses the real-world safety and efficacy data collected when using…